Fujimoto N, Itoh K, Kishikawa H, Tohda A, Takaha N, Kobayashi Y, Nakamori S, Sagawa S, Sonoda T
Department of Urology, Osaka Prefectural General Hospital.
Nihon Hinyokika Gakkai Zasshi. 1997 Sep;88(9):795-800. doi: 10.5980/jpnjurol1989.88.795.
Recent studies have shown that 99mTc-methoxy-isobutyl-isonitrile (99mTc-MIBI), a new agent for myocardial perfusion imaging, can be successfully applied to parathyroid imaging. We evaluated the efficacy of 99mTc-MIBI scintigraphy for preoperative localization of enlarged parathyroid glands in patients with hyperparathyroidism.
From June 1994 to September 1996, 24 patients with biochemical confirmation of hyperparathyroidism were studied with 99mTc-MIBI scintigraphy prior to operation. Eleven patients had primary hyperparathyroidism (PHPT) and 13 had secondary hyperparathyroidism (SHPT) associated with chronic renal failure, including one patient with recurrent disease after subtotal parathyroidectomy. A positive 99mTc-MIBI scan for an enlarged gland was defined as an area of persistent focal uptake on the delayed image acquired at 150 min after intravenous injection of 600 MBq of 99mTc-MIBI.
Of 11 patients with PHPT, 10, were found to have solitary parathyroid adenomas at surgery and one patient had primary hyperplasia. 99mTc-MIBI scintigraphy accurately detected 9 of 10 adenomas and 2 of 3 hyperplastic glands with no false positive results. Both of the two glands that were not detected by 99mTc-MIBI weighed 200 mg. The mean weight of the 11 glands that were visualized was 1264 mg (range 300 approximately 4300 mg). The sensitivity and predictive value positive for PHPT were 84.6% and 100%, respectively. In 13 patients with SHPT, all of 49 parathyroid glands were identified during surgery, with 43 hyperplastic glands and 6 normal-size glands. Of 43 hyperplastic glands, 28 were detected by 99mTc-MIBI and there was significant difference between the mean weight of these 28 glands (999 mg, range 290 approximately 2630 mg) and that of the 15 nonimaged hyperplastic glands (283 mg, range 90 approximately 540 mg). None of the six normal glands were imaged with 99mTc-MIBI. One patient had a false positive scan caused by a thyroid nodule. The sensitivity and predictive value positive for SHPT were 65.1% and 96.6%, respectively.
99mTc-MIBI scintigraphy is an excellent imaging method for localization of enlarged parathyroid glands in patients with hyperparathyroidism, especially with PHPT. However, it has the difficulty to demonstrate enlarged glands smaller than 300 mg in weight.
最近的研究表明,一种用于心肌灌注显像的新型药物锝-甲氧基异丁基异腈(99mTc-MIBI)可成功应用于甲状旁腺显像。我们评估了99mTc-MIBI闪烁显像术在甲状旁腺功能亢进患者术前定位增大的甲状旁腺方面的有效性。
1994年6月至1996年9月,对24例经生化检查确诊为甲状旁腺功能亢进的患者在手术前行99mTc-MIBI闪烁显像术检查。11例患者为原发性甲状旁腺功能亢进(PHPT),13例为与慢性肾功能衰竭相关的继发性甲状旁腺功能亢进(SHPT),其中1例患者在甲状旁腺次全切除术后复发。静脉注射600MBq的99mTc-MIBI后150分钟采集的延迟图像上持续存在局灶性摄取区域被定义为99mTc-MIBI扫描显示增大腺体阳性。
11例PHPT患者中,10例在手术中发现为孤立性甲状旁腺腺瘤,1例为原发性增生。99mTc-MIBI闪烁显像术准确检测出10例腺瘤中的9例和3例增生腺体中的2例,无假阳性结果。99mTc-MIBI未检测到的2个腺体重量均为200mg。显影的11个腺体平均重量为1264mg(范围300至4300mg)。PHPT的敏感性和阳性预测值分别为84.6%和100%。13例SHPT患者中,手术中识别出全部49个甲状旁腺,其中43个为增生腺体,6个为正常大小腺体。43个增生腺体中,28个被99mTc-MIBI检测到,这28个腺体的平均重量(999mg,范围290至2630mg)与15个未显影的增生腺体的平均重量(283mg,范围90至540mg)之间存在显著差异。6个正常腺体均未被99mTc-MIBI显影。1例患者因甲状腺结节导致假阳性扫描。SHPT的敏感性和阳性预测值分别为65.1%和96.6%。
99mTc-MIBI闪烁显像术是甲状旁腺功能亢进患者,尤其是PHPT患者中定位增大甲状旁腺的一种优秀成像方法。然而,它难以显示重量小于300mg的增大腺体。